Cell Therapy for Craniofacial Bone Defects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Cleft PalateTrauma
Interventions
BIOLOGICAL

Ixmyelocel-T

Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)

PROCEDURE

Autogenous Bone Grafting

Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.

Trial Locations (1)

48106

Michigan Center for Oral Health Research, Ann Arbor

All Listed Sponsors
lead

University of Michigan

OTHER

NCT01616953 - Cell Therapy for Craniofacial Bone Defects | Biotech Hunter | Biotech Hunter